Novo Nordisk A S (NVO) financials: revenue, earnings and cash flow
Fiscal 2019–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Novo Nordisk A S’s revenue went from $18.3B in fiscal 2019 to $48.6B in fiscal 2025, growth of about 17.6% a year.
Net income in fiscal 2025 was $16.1B, a net margin of 33.1%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $49.2B and net income $16.7B.
Free cash flow was $9.3B in fiscal 2025 and positive in 7 of the 7 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $49.2B | $48.6B | $40.5B | $34.4B | $25.4B | $21.4B | $20.9B | $18.3B |
| Gross profit | — | $39.4B | $34.3B | $29.1B | $21.3B | $17.8B | $17.5B | $15.3B |
| Operating income | — | $20.1B | $17.9B | $15.2B | $10.7B | $8.9B | $8.9B | $7.9B |
| Net income | $16.7B | $16.1B | $14.1B | $12.4B | $8.0B | $7.3B | $6.9B | $5.9B |
| EPS (diluted) | $3.76 | $3.64 | $3.18 | $2.80 | $1.80 | $1.64 | $1.57 | $1.32 |
| R&D | — | — | — | — | — | — | — | — |
| Revenue growth | — | +20.2% | +17.5% | +35.7% | +18.4% | +2.4% | +14.1% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $18.8B | $18.7B | $16.9B | $16.1B | $11.3B | $8.4B | $8.6B | $7.0B |
| Capital spending | -$12.1B | -$9.5B | -$6.6B | -$3.8B | -$1.7B | -$965M | -$961M | -$1.3B |
| Free cash flow | $6.6B | $9.3B | $10.3B | $12.3B | $9.6B | $7.4B | $7.6B | $5.7B |
| Dividends paid | $7.7B | $8.1B | $6.1B | $4.7B | $3.6B | $3.3B | $3.3B | $2.9B |
| Buybacks | — | $218M | $2.8B | $4.4B | $3.5B | $3.0B | $2.8B | $2.3B |
| Stock-based pay | — | $226M | $319M | $319M | $221M | $158M | $136M | $55M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash | — | $4.2B | $2.2B | $2.1B | $1.8B | $1.6B | $2.0B | $2.3B |
| Debt | — | $20.6B | $14.3B | $4.0B | $3.7B | $4.1B | $1.7B | $674M |
| Equity | — | $30.5B | $20.0B | $15.8B | $12.0B | $10.8B | $10.4B | $8.7B |
| Total assets | — | $85.4B | $64.9B | $46.6B | $34.6B | $29.6B | $23.9B | — |
| Shares (diluted) | 4.44B | 4.43B | 4.43B | 4.43B | 4.43B | 4.43B | 4.43B | 4.43B |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 81.0% | 84.7% | 84.6% | 83.9% | 83.2% | 83.5% | 83.5% |
| Operating margin | — | 41.3% | 44.2% | 44.2% | 42.3% | 41.6% | 42.6% | 43.0% |
| Net margin | 33.9% | 33.1% | 34.8% | 36.0% | 31.4% | 33.9% | 33.2% | 31.9% |
| FCF margin | 13.5% | 19.1% | 25.4% | 35.8% | 37.7% | 34.6% | 36.3% | 31.0% |
| ROIC | — | 30.8% | 41.4% | 61.4% | 55.0% | 48.7% | 58.3% | 67.8% |
| ROE | — | 52.8% | 70.4% | 78.5% | 66.5% | 67.5% | 66.5% | 67.6% |
Frequently asked questions
What is Novo Nordisk A S’s annual revenue?
$48.6B in fiscal 2025 and $49.2B over the twelve months to September 30, 2026.
How much profit does Novo Nordisk A S make?
Net income was $16.1B in fiscal 2025 (net margin 33.1%).
Is Novo Nordisk A S’s revenue growing?
Yes: revenue rose 20.2% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.